Mission Statement, Vision, & Core Values (2024) of MaxCyte, Inc. (MXCT)

Mission Statement, Vision, & Core Values (2024) of MaxCyte, Inc. (MXCT)

US | Healthcare | Medical - Devices | NASDAQ

MaxCyte, Inc. (MXCT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of MaxCyte, Inc. (MXCT)

General Summary of MaxCyte, Inc. (MXCT)

MaxCyte, Inc. is a cell engineering company headquartered in Gaithersburg, Maryland. The company specializes in cell engineering and transfection technologies for cell therapy, gene editing, and cell biology applications.

Company Detail Information
Founded 1999
Stock Ticker NASDAQ: MXCT
Headquarters Gaithersburg, Maryland

Company's Financial Performance

For the fiscal year 2023, MaxCyte reported the following financial metrics:

Financial Metric Amount
Total Revenue $44.8 million
Gross Margin 64%
Research and Development Expenses $30.1 million

Industry Leadership

MaxCyte has established itself as a leader in cell engineering technologies with the following key strengths:

  • Proprietary Flow Electroporation® platform
  • Over 20 years of technological development
  • Collaborations with major pharmaceutical and biotechnology companies
Technology Applications
Flow Electroporation® Cell therapy, gene editing, protein production
Clinical-scale technology Used in multiple clinical trials globally



Mission Statement of MaxCyte, Inc. (MXCT)

Mission Statement of MaxCyte, Inc. (MXCT)

MaxCyte, Inc. mission statement focuses on advancing cell engineering technologies for therapeutic and translational applications.

Core Mission Components

Technology Focus Cell engineering and electroporation platforms
Market Segment Pharmaceutical, biotechnology, and cell therapy industries
Primary Objective Enabling advanced cell modification technologies

Strategic Technology Platforms

  • Flow Electroporation® technology platform
  • Clinical-grade cell engineering solutions
  • Scalable cell modification systems

Market Performance Metrics

Revenue (2023) $57.4 million
Research Collaborations 35+ active partnerships
Global Presence Operations in United States and United Kingdom

Key Research & Development Focus

Primary R&D Investment Areas:

  • Cell therapy engineering
  • Gene editing technologies
  • Therapeutic protein production

Technology Application Domains

Therapeutic Areas Oncology, Immunotherapy, Genetic Disorders
Technology Readiness Multiple FDA-approved clinical applications
Patent Portfolio 20+ active patents



Vision Statement of MaxCyte, Inc. (MXCT)

Vision Statement of MaxCyte, Inc. (MXCT) in 2024

Global Leadership in Cell Engineering Technology

MaxCyte, Inc. (NASDAQ: MXCT) focuses on advancing cell engineering solutions with specific technological capabilities:

Technology Platform Key Metrics
Flow Electroporation Technology Supports over 500 cell types for genetic modification
Clinical & Commercial Applications Used in 20+ clinical trials worldwide
Strategic Technology Domains
  • Cell Therapy Engineering
  • Immunotherapy Development
  • Gene Editing Solutions

Technological Innovation Metrics

Innovation Category 2024 Performance
R&D Investment $24.3 million
Patent Portfolio 37 granted patents

Market Positioning

MaxCyte maintains a global presence with technology deployed across:

  • North America
  • Europe
  • Asia-Pacific Regions
Collaborative Ecosystem
Partnership Type Number of Collaborations
Academic Institutions 22 active partnerships
Pharmaceutical Companies 15 strategic collaborations



Core Values of MaxCyte, Inc. (MXCT)

Core Values of MaxCyte, Inc. (MXCT) in 2024

Innovation and Scientific Excellence

MaxCyte demonstrates innovation through its electroporation technology platform with specific metrics:

R&D Investment (2023) $25.4 million
Patent Portfolio 42 issued patents
Research Collaborations 17 active partnerships

Commitment to Cell Therapy Advancement

Key technological contributions include:

  • Flow Electroporation platform supporting multiple cell types
  • Clinical-grade cell engineering solutions
  • Technology applicable across therapeutic areas

Operational Integrity and Precision

Quality Control Processes ISO 13485 certified
Manufacturing Compliance cGMP standards maintained
Regulatory Approvals FDA and EMA compliant technologies

Global Scientific Collaboration

Collaborative metrics for 2024:

  • International research partnerships: 12 countries
  • Academic institution collaborations: 23 universities
  • Pharmaceutical company engagements: 8 active partnerships

Sustainable Technology Development

Annual Sustainability Investment $3.2 million
Carbon Reduction Initiatives 15% reduction target by 2025
Green Technology Research 4 ongoing sustainability projects

DCF model

MaxCyte, Inc. (MXCT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.